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Graphical abstract 
 
 
Highlights  
The steroid metabolome during fetal-neonatal transition varies with sex and postnatal age.  
For 67 urinary steroid compounds normative values have been quantified by GC-MS for the first year 
of life.  
Highest concentrations are found for progesterone metabolites and glucocorticoids.  
In both sexes, most compounds peak at week 3 and decrease to 20% by week 25.  
Normative data for the urine steroid metabolome provide a powerful diagnostic tool. 
 
 
 
Abstract 
Context: Complex steroid disorders such as P450 oxidoreductase deficiency or apparent 
cortisone reductase deficiency may be recognized by steroid profiling using chromatographic 
mass spectrometric methods. These methods are highly specific and sensitive, and provide 
a complete spectrum of steroid metabolites in a single measurement of one sample which 
makes them superior to immunoassays. The steroid metabolome during the fetal-neonatal 
transition is characterized by a) the metabolites of the fetal-placental unit at birth, b) the fetal 
adrenal androgens until its involution 3-6 months postnatally, and c) the steroid metabolites 
produced by the developing endocrine organs. All these developmental events change the 
steroid metabolome in an age- and sex-dependent manner during the first year of life. 
Objective: The aim of this study was to provide normative values for the urinary steroid 
metabolome of healthy newborns at short time intervals in the first year of life.  
Methods: We conducted a prospective, longitudinal study to measure 67 urinary steroid 
metabolites in 21 male and 22 female term healthy newborn infants at 13 time-points from 
week 1 to week 49 of life. Urine samples were collected from newborn infants before 
discharge from hospital and from healthy infants at home. Steroid metabolites were 
measured by gas chromatography-mass spectrometry (GC-MS) and steroid concentrations 
corrected for urinary creatinine excretion were calculated. 
Results: 61 steroids showed age and 15 steroids sex specificity. Highest urinary steroid 
concentrations were found in both sexes for progesterone derivatives, in particular 20α-DH-
5α-DH-progesterone, and for highly polar 6α-hydroxylated glucocorticoids. The steroids 
peaked at week 3 and decreased by ~80% at week 25 in both sexes. The decline of 
progestins, androgens and estrogens was more pronounced than of glucocorticoids whereas 
the excretion of corticosterone and its metabolites and of mineralocorticoids remained 
constant during the first year of life. 
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Conclusion: The urinary steroid profile changes dramatically during the first year of life and 
correlates with the physiologic developmental changes during the fetal-neonatal transition. 
Thus detailed normative data during this time period permit the use of steroid profiling as a 
powerful diagnostic tool. 
 
Keywords: newborn infants, gas chromatography-mass spectrometry, urinary steroid 
profile, reference values 
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1 Introduction 
Steroid hormones regulate various biological processes including salt balance, sexual 
development, reproductive function, and immune and stress responses. Because the 
secretion of each steroid hormone may vary with age and sex, especially in the newborn 
period during adjustment to extra-uterine life and fetal adrenal involution, detailed normative 
data are needed for effective quantitative assessment of steroids.  
For the urine metabolome during fetal-neonatal transition, Shackleton [1] has defined three 
groups: 1) steroid metabolites derived from the fetal-placental unit which are expected to 
vanish off rapidly in the newborn after birth; 2) metabolites produced by the fetal adrenal 
zone which should decrease parallel to its involution during the first 3-6 months after birth; 3) 
steroid metabolites derived from the developing endocrine cells and organs of the growing 
newborn. During fetal life steroids are mainly produced in the fetal zone of the adrenal 
glands, the testes (the ovaries being quiescent), the placenta and the brain [2, 3]. 
Postnatally, the fetal adrenal, which abundantly produces 19-carbon (C19) steroids (DHEA, 
DHEAS, androstenedione), involutes within 3-6 months [4]. After birth the adult adrenal 
cortex in its zonae glomerulosa and fasciculata produces mineralocorticoids and 
glucocorticoids. As adjusted for body surface area, cortisol secretion is essentially constant 
throughout postnatal life and shows little sex difference (except during pregnancy, when 
cortisol secretory rates increase), whereas aldosterone concentrations are very high in the 
newborn, drop rapidly during the first year, then continue to fall during childhood [4, 5]. The 
zona reticularis of the adult adrenal cortex is formed slowly during infancy to become active 
in C19 steroid production during adrenarche at 7-10 years. Testicular steroidogenesis is very 
active in the production of androgens in the male fetus, then declines after birth with a 
temporary increase during minipuberty between postnatal days 30-100 before going into the 
quiescent prepubertal phase [5]. By contrast, estrogens are low from infancy until puberty as 
the prepubertal ovary is quiescent [4, 5].  
Steroid hormones can be grouped according to their receptor binding into progestins, 
androgens, estrogens, mineralocorticoids and glucocorticoids. The biochemistry of steroid 
biosynthesis and metabolism is largely known and specific steroid pathways are regulated 
by differential expression and activity of enzymes and cofactors involved in a developmental, 
sex, time and tissue specific fashion which might be perturbed in disease states [4, 5]. Once 
steroids are produced in steroidogenic tissues, they enter the circulation and are converted 
into a large number of metabolites by the liver and peripheral tissues before being excreted 
in the urine. Thus, all these processes contribute towards the steroid metabolome, which 
may be characterized from biomaterials such as blood or urine, and serves as an excellent 
diagnostic tool. 
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In the past, some effort has been made to generate quantitative data for the urinary steroid 
metabolome in newborns (for an overview see Appendix Table A) [1, 6-11]. However, 
detailed normative data are lacking for the first year of life when many changes happen over 
short time intervals in healthy babies; normative data are also needed to distinguish 
physiologic alterations from inborn errors of metabolism in sick babies. Simultaneous 
measurements of the full spectrum of urinary steroids by GC-MS provide a comprehensive 
and integrated picture of the steroid metabolome, permitting accurate diagnosis of disorders 
of steroid biosynthesis and metabolism in newborn infants [12]. In addition, the non-invasive 
sampling and the requirement of small amounts of spot urine make this method very suitable 
for infants and small children. 
We intended to describe and quantitate the urinary steroid metabolome of healthy infants 
longitudinally at high resolution time intervals during the first year of life using GC-MS. We 
analyzed the 67 measured steroids for sex differences and longitudinal changes that might 
indicate underlying developmental processes for each measured steroid and for steroid 
groups. Our study now provides detailed normative data in percentile curves for 67 steroid 
metabolites during the first year of life. We show that there are few sex-specific differences 
but that there are significant longitudinal changes that relate to developmental changes in 
steroidogenesis during fetal-neonatal transition. 
 
 
2 Material and Methods 
2.1 Study population 
The local medical ethics committee approved the study protocol, and the parents provided 
written informed consent. Healthy newborn infants and their parents were recruited from 
June 2010 to March 2012 at the University Children’s Hospital Bern, Inselspital, the 
Lindenhofspital Bern and the Spital Münsingen, Bern, Switzerland. Inclusion criteria were: 
Caucasian healthy boys and girls, born at term with normal weight and length, either by 
vaginal delivery or Caesarian section, willingness of the parents to collect 13 urine samples 
throughout the first year of life and to report on the health status of their baby (including 
weight and length at each urine sampling timepoint). We recruited 43 subjects (22 girls and 
21 boys) and obtained samples at 13 time points, for an anticipated total of 559 samples. 
Drop-outs were due to the following reasons: stop of sampling or non-compliance with 
sampling schedule, occurence of disease and drug treatments or errors in measuring 
steroids and/or creatinine. 
 
2.2 Urine collection procedure 
Urine samples were collected from each study subject in weeks 1, 3, 5, 7, 9, 11, 13, 17, 21, 
25, 33, 41, and 49 of life if healthy and receiving no medication. A maximal deviation of ±7 
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days from this time schedule was tolerated, except for week 1 where a deviation of only ±3 
days was permitted. Clean spot urines were collected from pure cotton balls inserted into 
regular diapers. Wet cotton balls, free of stool, were removed and urine was pressed out 
with a 50 ml syringe into a labeled tube. Samples were stored at -20°C and were 
subsequently sent to the steroid laboratory of the Department of Nephrology, Hypertension 
and Clinical Pharmacology at the University Hospital of Bern, Switzerland, for GC-MS steroid 
analysis. Validity and stability of this urine collection method for steroid analysis has been 
previously reported [13-15]. Minimal urine volume required for steroid analysis was 200 µl, 
standard volume was 1.5 ml; for creatinine measurement 5 µl urine was used. 
 
2.3 Measurement of urinary steroid metabolites and creatinine 
Quantitative analysis of 67 different urinary steroid hormone metabolites was performed by 
an in-house adapted GC-MS method as previously described [16-19]. All measurements 
were performed in the same steroid laboratory of the Department of Nephrology, 
Hypertension and Clinical Pharmacology at the University Hospital of Bern, Switzerland. 
Measured steroids are listed in Table 1 and depicted in Figure 1. 
Standards, reagents and enzymes were obtained as follows: The steroids 
medroxyprogesterone, stigmasterol, and 3β5β-TH-aldosterone were obtained from 
Steraloids (Newport RI, USA), the Sep-Pak C18 column from Waters AG (Baden-Dättwil, 
Switzerland), the acetate buffer from Merck (Zug, Switzerland), the powdered sulfatase 
enzyme originated from Helix pomatia from Sigma-Aldrich Chemie GmbH (Buchs, 
Switzerland), the β-glucuronidase/arylsulfatase liquid enzyme from Roche Diagnostics AG 
(Rotkreuz, Switzerland), the derivatives methoxyamine HCl 2% and the 
trimethylsilylimidazole (TMSI) from Thermo Scientific (Waltham MA, USA), the pyridine from 
company (city, country), the Lipidex 5000 from Perkin Elmer (Waltham MA, USA). 
In brief, the urine sample preparation consisted of pre-extraction, enzymatic hydrolysis, 
extraction from the hydrolysis mixture, derivatization and gel filtration. Steroid profiles data 
were obtained by adapted GC-MS analysis according to methods reported by Shackleton 
[16]. In detail, the preanalytic procedures were as follows: Step 1, to 1.5 ml of urine 2.5 µg of 
medroxyprogesterone was added as a recovery standard. Step 2, the sample was extracted 
by solid phase extraction on a Sep-Pak C18 column, dried under nitrogen and reconstituted 
in 0.1 M acetate buffer (pH 4.6). Step 3, the sample was hydrolyzed with 15 mg of powdered 
sulfatase enzyme and 15 µl of β-glucuronidase/arylsulfatase liquid enzyme before step 4, 
the free steroids were again extracted on a Sep-Pak C18 cartridge. During step 5, a mixture 
of standards for chromatography and derivatization consisting of 2.5 µg of Stigmasterol and 
0.15 µg of 3β5β-TH-aldosterone was added to the extract. Step 6, 100 µl of methoxyamine 
HCl 2% in pyridine was added and the samples were heated at 60°C for one hour. Step 7, 
after evaporation of the solvent 100 µl of trimethylsilylimidazole (TMSI) was added and the 
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extracts were heated at 100°C for 16 hours. Step 8, the methyloxime-trimethylsilyl ethers 
derivatized samples were purified by gel filtration on Lipidex 5000 columns to remove the 
excess of derivatization reagent. In three samples, the urine volume available was 200 µl 
only. For that case and future use, we re-validated our method for reduced sample volume 
and give all data of intra- and inter-assay variations for standard and reduced volume in 
Appendix Table B. 
Mass spectrometric analyses were performed on a gas chromatograph 7890A from Agilent 
Technologies (La Jolla, California, USA) coupled to a mass selective detector Hewlett-
Packard 5975C providing selected ion monitoring (SIM). For each compound measured, one 
characteristic ion was monitored. The derivatized samples were analyzed during a 
temperature programmed run (210-265°C) over a 35-minute period. A mixture containing a 
known amount of all steroids measured was analyzed on a regular basis to act as a 
calibration standard. Recoveries were checked with medroxyprogesterone and corrections 
were made for the losses occurring during sample preparation. In Appendix Table C the 
steroid metabolites measured in this study and their molar mass, each selected compound-
specific qualifier ion, the retention time and the limits of detection and of quantitation are 
given. Due to lack of reference materials, the five compounds 6α-OH-TH-cortisone, 1β-OH-
TH-cortisone, 1β-OH-β-cortolone, 6α-OH-α-cortolone and 6α-OH-β-cortolone were 
calibrated and measured according to the procedure published by Caulfield et al. [8]. 
Neonatal urine from the first collection after birth containing high amounts of these steroids 
was analyzed by GC-MS in the scanning mode and the total ion current (TIC) peak areas of 
the five identified compounds were integrated and were related to the standard Stigmasterol. 
Based on the assumption that peak area responses in TIC of different compounds were 
identical for components of similar retention time, we determined the approximate 
concentration of these compounds in the urine and they were finally analyzed again in the 
SIM mode to obtain calibration responses which were used to quantify the five compounds in 
the study samples. For all steroids, measured specific peaks in the chromatograms had to 
be three times higher as the noise above the baseline to be counted as valid measurements 
(signal-to-noise-ratio ≥3).  
Urinary creatinine was measured by quantitative colorimetry using the QuantiChrom 
Creatinine Assay according to the manufacturer’s recommendation (DICT-500; BioAssay 
Systems, Hayward, CA, USA). 
Since spot urines were collected, measured steroids were standardized by urinary creatinine 
concentration and expressed in µg/mmol creatinine [20, 21]. 
 
2.4 Quality control of the applied GC-MS method 
The reproducibility of our in-house GC-MS method is continuously monitored by an internal 
quality control. For this purpose 15 samples of frozen aliquots from the urine of a healthy 
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volunteer with an unremarkable urinary steroid profile were measured and means, standard 
deviations, and the coefficients of variation for all steroid metabolites were calculated as 
standard values. Two samples of this urine served as internal quality control in all 
measurement series and the results of the two analyses were regularly compared with the 
standard values. 
Since 10 years we and 27 other laboratories from all over the world participate regularly in 
an external quality control organized by the University College London Hospitals (London, 
United Kingdom) and by the Foundation for Quality Medical Laboratory Diagnostics skml 
(Stichting Kwaliteitsbewaking Medische Laboratoriumdiagnostiek, Nijmegen, The 
Netherlands). For that, at the beginning of each year every laboratory receives 12 lyophilized 
urines, of which a specific one is dissolved every month in water and analyzed like a patient 
sample. The results of the analysis are sent together with an interpretive comment, a 
proposal for further investigations and a chromatogram to the reference laboratory. The 
individual urinary steroid values of each laboratory are compared with the median value of all 
participants, the multiple of the median (MoM) is calculated for each steroid metabolite and 
the average MoM is given for each laboratory. Each laboratory gets a score for the analytical 
results as well as for the comment and the chromatogram. At the end of the year, a ranking 
for the steroid analysis, for the comment and an overall ranking is calculated for all 28 
laboratories by the organizers. 
 
2.5 Statistical analysis 
Baseline characteristics of the study population are presented as mean, standard deviation, 
median and range unless otherwise stated. All normalized urinary steroid hormones were 
modeled on the logarithmic scale, where the variance was roughly constant across the ages. 
The age and sex dependent mean of each log-steroid was estimated using a linear mixed 
model which included a random subject effect to account for the dependence induced by the 
repeated measurements within the subject. To allow a flexible modelling of the age-
dependence of various steroids, we considered the following six possible age-effects: 
constant (corresponding to no age effect), linear, quadratic, quadratic spline with one knot, 
quadratic spline with one knot and a constraint of levelling-off, quadratic spline with two 
knots and a constraint of levelling-off. The knots have been selected using a grid search in 
order to optimize the fit, while a constraint of levelling-off, allowing to model a plateau 
reached after some age, can be easily imposed using B-splines [22-24]. Since we 
considered to include a sex effect in the model, we fitted a total of 12 possible models for 
each steroid and selected that model minimizing the Akaike Information Criterion. We let 
thus the data decide whether or not an age or a sex effect should be included in the model. 
The detailed model selection process is described in Appendix Methods B. Normative values 
of the study population were fitted from the model that was finally selected and are 
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presented as the 10th, 50th and 90th percentiles and curves for each steroid. Data are 
presented for steroid groups and time-points as well as separately for male and female 
infants when a model with a sex effect was selected. Steroid hormones were grouped 
according to their receptor binding into progestins, androgens, estrogens, mineralocorticoids 
and glucocorticoids. As corticosterones can bind to both the mineralocorticoid receptors and 
the glucocorticoid receptors we decided to form a separate group for them. Inactive steroid 
metabolites which do not bind to a receptor (e.g. 17-hydroxyprogesterone and the 
progesterone receptor), were included in the group of steroids of the most proximal active 
precursor steroid (e.g. group of progestins for 17-hydroxyprogesterone). Statistical analyses 
were performed using the software R including the lme4 package [25]. 
 
3 Results 
3.1 Study population and specimen characteristics 
Serial urine samples of 21 healthy boys and 22 healthy girls were available for analysis. The 
baseline characteristics of the study population stratified by sex at birth and at 1 year of age 
are presented in Table 2. From the recruited 43 subjects and 13 time-points, 26’914 values 
of creatinine corrected steroid compounds were included in the final analysis corresponding 
to 71.9 % of the maximal possible number of calculated values. 
 
3.2 Urinary steroid metabolome 
67 steroids (Figure 1 and Table 1) were assessed in each urine portion by GC-MS in 43 
babies at 13 time-points from birth to one year of age and tested for sex specificity and age-
related changes. Six of 12 possible models described in the method section allowed the best 
estimate of the log-steroid mean for characterization of all steroids.  
Two steroids, TH-aldosterone and 17α-20α-DH-progesterone, showed no association with 
age or sex. Four steroids, 11β-OH-progesterone, androstanediol, 18-OH-11-dehydro-TH-
corticosterone and 18-OH-cortisol showed an association with sex but not with age. An 
association with sex was found for 15 steroids. Age-related changes were observed in 61 
steroids, 50 within the group of steroids not specific for sex and 11 in the group of sex 
specific steroids. The 10th, 50th and 90th percentiles estimated for urinary steroids 
unassociated with sex are given in Table 3, and in Table 4, if sex-specific differences were 
detected. In both tables the association with age is also indicated. 
The median concentration of total excreted steroids at weeks 1, 3, 5 and 7 was estimated at 
29’379-36’906 µg/mmol creatinine in males and 20’959-26’330 µg/mmol creatinine in 
females (Figure 2A, B). A substantial decline in the excreted steroids then occurred in both 
sexes followed by constant excretion from weeks 33 to 49 in males (median concentration 
6’780 µg/mmol creatinine) and females (median concentration 4’837 µg/mmol creatinine).  
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Group analyses of steroid metabolites showing age- and sex-specific characteristics are 
shown in Figure 2C-L. A model with a sex effect but without an age effect was selected for 
corticosterones (Figure 2G, H), a model with an age and sex effect was selected for 
glucocorticoids (Figure 2J, K) and the total sum of steroids (Figures D, E), and a model with 
an age effect but without a sex effect was selected for progestins, androgens, estrogens and 
mineralocorticoids (Figure 2C, F, I and L). The resulting estimated percentiles fit the data 
nicely for most of the steroids and steroid groups, as can be seen in Figure 1 and the 
Appendix Fig. C.1-C.82, where the numbers of observations falling below, between and 
above the estimated 3rd, 10th, 25th, 50th, 75th, 90th and 97th percentiles were close to the 
theoretical values. Androgens and estrogens were markedly higher at birth and declined 
during the first 6 months, but the two measured estrogen metabolites were very low, even 
during the first week of life, when compared to androgens such as testosterone or 5α-DH-
testosterone. Similarly, progestins declined within 5-6 months after birth and remained 
constant thereafter. At week 1 glucocorticoids and progestins each contributed about one 
third to the total amount of excreted steroids in both males and females whereas androgens 
contributed about 15%. While the proportion of progestins and androgens declined during 
the first weeks of life, the proportion of excreted glucocorticoid metabolites increased 
constantly until week 21 when it comprised about 80% of the total amount of the excreted 
metabolites. The steroid metabolites with the highest urinary concentration in both sexes at 
nearly all time-points were 20α-DH-5α-DH-progesterone among the group of progestins, 6α-
OH-α-cortolone among the glucocorticoids, 5-androstenetriol among the androgens, estriol 
among the estrogens, and 11-dehydro-TH-corticosterone among the corticosterones (Table 
3 and 4). 
 
4 Discussion 
The recent discovery of novel, complex steroid disorders such as P450 oxidoreductase 
deficiency or apparent cortisone reductase deficiency highlight the diagnostic significance of 
the steroid metabolome [26-28]. Also, many now propose that steroids should no longer be 
measured by inaccurate immunoassays and that steroid assays should be replaced by mass 
spectrometric methods, which are highly specific and sensitive, while providing a full 
spectrum of steroid measurements in a single sample in one assay [29]. Although standard 
methods for steroid profiling from urine or plasma are known, they are only established in 
few laboratories and normative data are scarce. We have been using GC-MS for steroid 
profiling from urine for the past 25 years in our laboratory but did not have detailed normative 
data for neonates and infants in the first year of life. Although some normative data from 
other laboratories exist, data for the first year of life, when dramatic changes occur, are 
incomplete. Such normative data may not be applied for individual in-house methods without 
proper controls and are difficult to obtain. Therefore, to generate a comprehensive picture of 
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the steroid metabolome during early development, we measured 67 urinary steroids in 21 
male and 22 female full-term healthy infants at 13 different time-points from week 1 to week 
49 of life by GC-MS and calculated normative data using specifically developed mixed-linear 
models for each steroid. 
 
We used a statistical model that includes a flexible age-dependence to capture possible 
pattern of development among the various steroids. This model uses a limited number of 
variables to characterize the distribution of steroids at a given age, yielding a robust 
estimation of the high percentiles. We obtained explicit, flexible, smooth and robust age-
dependent and sex-dependent percentiles that were as close as possible to our data. With 
our steroid normative data percentiles we provide an easy tool for clinical use. 
 
Our steroid profiling results may be directly compared to previous reports of creatinine-
corrected urinary steroid metabolites; these are summarized in Appendix Table A. In 
particular, comparison is possible with the most comprehensive collection of urinary steroid 
metabolites so far assessed by Homma et al. who measured 50 steroid metabolites in 18 
babies aged 5-22 days [9]; of those 24 metabolites were also included in our study. We 
found similar results for 16 urinary steroids in the first weeks of life, specifically 17-OH-
pregnenolone, pregnanetriol, pregnanediol, androsterone, dehydroepiandrosterone, 11β-
OH-androsterone, 16α-OH-dehydroepiandrosterone, estradiol, 18-OH-11-DH-TH-
corticosterone, TH-aldosterone, TH-11-deoxycortisol, cortisone, TH-cortisone, α-cortolone, 
cortisol and 18-OH-cortisol [9]. Values more than 3-fold higher were found in our study for 
pregnanetriolone, pregnanediol, etiocholanolone, androstenediol, estriol, and 20α-DH-
cortisol while lower values were found for 20α-DH-cortisone and 20β-DH-cortisone. Similar 
to our study, Homma et al. also found no sex difference for most of the urinary steroid 
metabolites including the majority of the androgens [9]. Like Homma’s study, we found a sex 
difference for progesterone metabolites, but unlike Homma’s study, we found no sex 
difference for estradiol and estriol, and we found considerably higher estriol concentrations. 
These differences might be explained by technical limitations when measuring low levels. On 
the other hand, some of the observed differences may also be explained by differences in 
the genetic background of studied subjects affecting the steroid metabolome; e.g. while we 
studied Swiss infants, Homma et al. studied Japanese. 
We compared our steroid data concerning sex- and age-specificity to previous studies 
assessing 24 hour urinary excretion of steroid metabolites in the first year of life [10, 11]. 
Concerning sex-specificity, our results are in line with both published reports with the 
exception of allo-TH-cortisol, for which we found about 2-fold higher values in male infants 
during the first year of life similar to the study of Wudy et al [10], but different to the values 
reported by Rogers et al. [11]. Concerning age-specificity, we also found similar patterns of 
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urinary steroid excretion compared to Rogers et al. who demonstrated an increase for most 
cortisol metabolites during the first year of life [11]. However, we could not confirm the 
increase of total measured cortisol metabolites across the first year of life as described by 
Rogers et al. But this difference might be best explained by the fact that total glucocorticoid 
excretion consisted of 9 metabolites in Rogers’ study but 21 metabolites in ours. Thus the 
group results cannot be directly compared. Our glucocorticoid group analysis in particular 
included five highly polar 1β- and 6α-hydroxylated steroids (namely 1β-OH-TH-cortisone, 1β-
OH-β-cortolone, 6α-OH-TH-cortisone, 6α-OH-α-cortolone and 6α-OH-β-cortolone), of which 
specifically 6α-OH-α-cortolone was highest at birth, increased even further in the first weeks, 
before slightly decreasing and leveling off after week seven. 
Unlike urinary cortisol metabolites, we found only few published data on progesterone 
metabolites (progestins) to compare our study results (Table 3 and 4 and Appendix Table A). 
Our study provides data on 26 progestins, of which only normative data of five were reported 
and are in accordance with our values [8-10]. The highest measured progesterone 
metabolite in our study was 20α-DH-5α-DH-progesterone in both sexes from birth to one 
year of age. For this metabolite we found no measurements in the literature and its function 
is also not described. It might be that this is just the major highly polar metabolite to excrete 
progestins effectively without other function. Similar to our findings for cortisol metabolites, 
we found high urinary concentrations of polar 6α-hydroxylated progesterones, in particular 
6α-OH-progesterone and 6α-OH-3α5β-TH-progesterone, which were excreted at 
concentrations above 100 µg/mmol creatinine until week 13, that is much higher than most 
other progestins. 
In comparison to glucocorticoids, androgens and estrogens are excreted in considerably 
smaller amounts and decrease in the first months of life. This is explained by the underlying 
developmental changes of the steroid organs as described earlier (see Introduction).  
 
Overall, our data are largely in line with published results but expand the picture of the 
steroid metabolome of the first year of life by giving a higher resolution and more 
metabolites. Our data also confirm that the urinary steroid metabolome of a newborn can 
track normal and abnormal developmental processes of steroid organs and therefore 
provides an excellent, non-invasive diagnostic tool. 
 
The reference ranges published in this study will raise the question about their usefulness for 
other laboratories using slightly different methods. We are convinced that these data may be 
useful because we together with 27 other laboratories participate in a steroid profile scheme 
provided by the UK NEQAS (International Quality Expertise, www.ukneqas.org.uk). In this 
scheme data are compared as described in the Methods section. This assures quality of the 
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analysis and confirms that there are ways to compare steroid data generated by different 
laboratories.  
 
Limitations of our study are the rather small number of subjects (though one of the biggest to 
date) and urine collection mode. Although small in numbers, we studied our subjects 
longitudinally with short intervals, and are therefore able to provide statistically valid, 
calculated normative data. 24 hour urine collections in neonates and infants are 
cumbersome and mostly imprecise but provide real quantitative data of excreted 
metabolites, while spot urine sampling is easy to perform but requires calculation of excreted 
metabolites in relation to creatinine values. However, previous studies showed that spot 
urine measurements are valid for diagnostic purposes [30]. For group analysis, we have 
chosen to categorize the steroid metabolites according to their receptor binding. However, 
this choice left us with the problem that corticosterones bind to mineralocorticoid and 
glucocorticoid receptors which prompted us to put them in a separate group. Grouping of 
steroids is not standardized and may be performed differently according to study needs.  
 
 
5 Conclusions 
The following conclusions about the urinary steroid metabolome in the first year of life 
emerge from our analyses. First, the creatinine corrected concentration of urinary excreted 
steroids is high in infants during the first two months of life with a peak around 3 weeks of 
life. Then these steroids decrease to one fifth by week 25 in both sexes. Second, the pattern 
of urinary steroid excretion in the first year of life does not run parallel in all steroid groups. 
Glucocorticoid, mineralocorticoid and corticosterone metabolites seem to be excreted rather 
at a constant level while progestins, androgens and estrogens decline markedly within the 
first few months of life. Third, the urinary steroid metabolome mirrors the underlying 
developmental biology of human steroidogenesis and is therefore a powerful tool for steroid 
research and diagnostics. However, detailed age- and sex-related normative values are 
essential.  
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Legends to Figures and Tables:  
Table 1: Steroid metabolites measured in this study and their molar mass. The 
nomenclature of the systematic names follows the recommendations published by the 
IUPAC commission on the Nomenclature of Organic Chemistry in 1969 [32], amended by 
the IUPAC–IUB Commission on Biochemical Nomenclature in 1971 [33] and again revised in 
1989 [34]. OH: hydroxy, DH: dihydro, TH: tetrahydro. 
 
Table 2. Baseline characteristics of the study subjects dichotomized by sex. 
 
Table 3. Fifty-two urinary steroid metabolites at 13 time-points in the first year of life 
display no sex specificity. Age and sex dependency of each log-transformed steroid has 
been estimated the described statistical models. Data are presented as 10th-50th-90th 
percentiles and expressed in the unit µg / mmol Creatinine. N represents the sample number 
per analyte included in the statistical model. The association with age effect is indicated. 
 
Table 4. Fifteen urinary steroid metabolites at 13 time-points in the first year of life 
display sex specificity. Age and sex dependency of each log-transformed steroid has been 
estimated the described statistical models. Data are presented as 10th-50th-90th percentiles 
and expressed in the unit µg / mmol creatinine. The association with age effect is indicated. 
N represents the sample number per analyte, included in the statistical model. m: male, f: 
female 
 
Figure 1. Pathways of steroid hormone biosynthesis. Pathways from multiple cell types 
are combined to provide an overview of all possible biosynthesis processes. The 67 steroid 
metabolites measured in this study are highlighted by colored background according to their 
suggested receptor activity. Enzyme activities are displayed in blue color. Abbreviations: 
DHEA: Dehydroepiandrosterone. The OH in enzyme names indicates a hydroxylase, e.g. 
17α-OH: 17α-hydroxylase. The OH in steroid names indicates a hydroxyl group, e.g. 17-OH-
pregnelonone: 17-hydroxy-pregnelonone. DH: dehydro; TH: tetrahydro; HSD: hydroxysteroid 
dehydrogenase; POR: P450 oxidoreductase; Cyt b5: cytochrom b5; 5α-R: 5α-reductase; 5β-
R: 5β-reductase; CYP11B2: aldosterone synthase; C17,20-lyase2: yet undefined lyase, that 
removes the side-chain of 17-OH-corticosteroids [31]. 
 
Figure 2. Urinary steroid excretion in µg/mmol creatinine by sex and age in the first 
year of life. Note the logarithmic scaling of all Y-axes. A and B. Longitudinal comparison of 
the total urinary steroid excretion and the steroid excretion by steroid groups in boys (A) and 
girls (B). C-L. Estimated percentile curves for urinary steroid metabolites by sex and age. 
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The solid lines represent the 50th and the dashed lines the 3rd, 10th, 25th, 75th, 75th, 90th, and 
97th percentiles as indicated based on the described statistical models. 
 
 
 
Table 1: Steroid metabolites measured in this study and their molar mass. The 
nomenclature of the systematic names follows the recommendations published by the IUPAC 
commission on the Nomenclature of Organic Chemistry in 1969 [32], amended by the 
IUPAC–IUB Commission on Biochemical Nomenclature in 1971 [33] and again revised in 
1989 [34]. OH: hydroxy, DH: dihydro, TH: tetrahydro. 
Trivial name Systematic name Molar mass
Progesterones     
progesterone 4-pregnene-3,20-dione 
6α-OH-progesterone 6α-hydroxy-4-pregnene-3,20-dione 
6β-OH-progesterone 6β-hydroxy-4-pregnene-3,20-dione 
11α-OH-progesterone 11α-hydroxy-4-pregnene-3,20-dione 
11β-OH-progesterone 11β-hydroxy-4-pregnene-3,20-dione 
11-keto-progesterone 4-pregnene-3,11,20-trione 
17α-OH-progesterone 17α-hydroxy-4-pregnene-3,20-dione 
17-OH-pregnanolone 3β,17-dihydroxy-5-pregnen-20-one 
pregnanetriol 5β-pregnane-3α,17α,20α-triol 
pregnenetriol 5-pregnene-3β,17α,20α-triol 
pregnanetriolone 3α,17α,20α-trihydroxy-5β-pregnan-11-one 
5α-DH-progesterone 5α-pregnane-3,20-dione 
3α5α-TH-progesterone / allopregnanolone 3α-hydroxy-5α-pregnan-20-one 
3β5α-TH-progesterone / isopregnanolone 3β-hydroxy-5α-pregnan-20-one 
5β-DH-progesterone 5β-pregnane-3,20-dione 
3α5β-TH-progesterone / epipregnanolone 3α-hydroxy-5β-pregnan-20-one 
6α-OH-3α5β-TH-progesterone  3α,6α-dihydroxy-5β-pregnan-20-one 
3β5β-TH-progesterone / pregnanolone 3β-hydroxy-5β-pregnan-20-one 
20α-DH-progesterone 20α-hydroxy-4-pregnen-3-one 
17α-OH-20α-DH-progesterone 17α,20α-dihydroxy-4-pregnene-3,20-dione 
20α-DH-5α-DH-progesterone 20α-hydroxy-5α-pregnan-3-one 
20α-DH-3α5α-TH-progesterone / allopregnanediol 5α-pregnane-3α,20α-diol 
20α-DH-3β5α-TH-progesterone 5α-pregnane-3β,20α-diol 
20α-DH-3α5β-TH-progesterone / pregnanediol 5β-pregnane-3α,20α-diol 
20α-DH-3β5β-TH-progesterone 5β-pregnane-3β,20α-diol 
20β-DH-progesterone 20β-hydroxy-4-pregnen-3-one 
Androgens     
dehydroepiandrosterone 3β-hydroxy-5-androsten-17-one 
16α-OH-dehydroepiandrosterone 3β,16α-dihydroxy-5-androsten-17-one 
androstenediol 5-androstene-3β,17β-diol 
testosterone 17β-hydroxy-4-androsten-3-one 
5α-DH-testosterone 17β-hydroxy-5α-androstan-3-one  
androstanediol /dihydroandrosterone 5α-androstane-3α,17β-diol 
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Trivial name Systematic name Molar mass
androsterone 3α-hydroxy-5α-androstan-17-one 
5-androstenetriol 5-androstene-3β,16α,17β-triol 
11β-OH-androsterone 3α,11β-dihydroxy-5α-androstan-17-one 
etiocholanolone 3α-Hydroxy-5β-androstan-17-one 
Estrogens     
17β-estradiol 1,3,5(10)-estratriene-3,17β-diol 
estriol 1,3,5(10)-estratriene-3,16α,17β-triol 
Corticosterones     
11-deoxycorticosterone 21-hydroxy-pregnene-3,20-dione 
11-deoxy-TH-corticosterone 3α,21-dihydroxy-5β-pregnan-20-one 
11-dehydro-TH-corticosterone 3α,21-dihydroxy-5β-pregnane-11,20-dione 
18-OH-11-dehydro-TH-corticosterone 3α,18,21-trihydroxy-5β-pregnane-11,20-dione 
TH-corticosterone 3α,11β,21-trihydroxy-5β-pregnan-20-one 
allo-TH-corticosterone 3α,11β,21-trihydroxy-5α-pregnan-20-one 
Mineralocorticoids     
TH-aldosterone 11β,18-epoxy-3α,18,21-trihydroxy-5β-pregnan-20-one 
TH-11-deoxycortisol 3α,17,21-trihydroxy-5β-pregnan-20-one 
Glucocorticoids     
cortisol 11β,17,21-trihydroxy-4-pregnene-3,20-dione 
6β-OH-cortisol 6β,11β,17α,21-tetrahydroxy-4-pregnene-3,20-dione 
18-OH-cortisol 11,17,18,21-tetrahydroxy-4-pregnene-3,20-dione 
20α-DH-cortisol 11β,17,20α,21-tetrahydroxy-4-pregnen-3-one 
TH-cortisol 3α,11β,17,21-tetrahydroxy-5β-pregnan-20-one 
α-cortol 5β-pregnane-3α,11β,17α,20α,21-pentol 
β-cortol 5β-pregnane-3α,11β,17α,20β,21-pentol 
11β-OH-etiocholanolone 3α,11β-dihydroxy-5β-androstan-17-one 
allo-TH-cortisol 3α,11β,17,21-tetrahydroxy-5α-pregnan-20-one 
cortisone 17,21-dihydroxy-4-pregnene-3,11,20-trione 
20α-DH-cortisone 17α,20α,21-trihydroxy-4-pregnene-3,11-dione 
20β-DH-cortisone 17α,20β,21-trihydroxy-4-pregnene-3,11-dione 
TH-cortisone 3α,17,21-trihydroxy-5β-pregnan-11,20-dione 
1β-OH-TH-cortisone 1β,3α,17,21-tetrahydroxy-5β-pregnan-11,20-dione 
6α-OH-TH-cortisone 3α,6,17,21-tetrahydroxy-5β-pregnan-11,20-dione 
α-cortolone 3α,17α,20α,21-tetrahydroxy-5β-pregnane-11-one 
6α-OH-α-cortolone 3α,6α,17α,20α,21-pentahydroxy-5β-pregnane-11-one 
β-cortolone 3α,17α,20β,21-tetrahydroxy-5β-pregnane-11-one 
1β-OH-β-cortolone 1β,6α,17α,20β,21-pentahydroxy-5β-pregnane-11-one 
6α-OH-β-cortolone 3α,6α,17α,20β,21-pentahydroxy-5β-pregnane-11-one 
11-keto-etiocholanolone / 11-oxo-etiocholanolone 3α-hydroxy-5β-androstane-11,17-dione 
Table 2 Baseline characteristics of the study subjects dichotomized by sex. 
  Female Male All 
n 22 21 43 
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  Female Male All 
n 22 21 43 
Vaginal delivery 16 15 31 
Birth weight (g) - mean 3253 3281 3267 
BW (g) - median 3400 3270 3390 
BW (SDS) -0.33 -0.58 -0.45 
BW (g) range 2560-4000 2400-3860 2400-4000 
Weight at 1 year (kg) - mean 9.19 9.86 9.52 
W1y (kg) - median 8.9 9.69 9.5 
W1y (mean - SD) -0.34 -0.3 -0.32 
W1y (kg) range 7.4-11.9 8.3-11.2 7.4-11.9 
Table 3. Fifty-two urinary steroid metabolites at 13 time-points in the first year of life 
display no sex specificity. Age and sex dependency of each log-transformed steroid has been 
estimated the described statistical models. Data are presented as 10th-50th-90th percentiles 
and expressed in the unit μg / mmol Creatinine. N represents the sample number per analyte 
included in the statistical model. The association with age effect is indicated. 
   Week 1 Week 3 Week 5 Week 7 Week 9 Week 11 Week 13 Week 17 
Week 
21
Metabolite N 10
th-50th-
90th 
10th-50th-
90th 
10th-50th-
90th 
10th-50th-
90th 
10th-50th-
90th 
10th-50th-
90th 
10th-50th-
90th 
10th-50th-
90th 
10
50
6α-OH-progesterone 36235-312-2073 
27-242-
1609 
22-190-
1264 
17-151-
1004 
14-121-
806 
11-98-
655 9-81-538 6-56-375 
5
274
6β-OH-progesterone 3602-11-108 1-8-82 1-7-64 1-5-50 1-4-39 0-3-31 0-3-26 0-2-17 0
17α-OH-progesterone 36120-65-175 
16-52-
141 
13-42-
114 11-34-93 9-28-76 7-23-63 6-19-53 4-14-38 3
17-OH-pregnanolone 4243-10-30 2-10-28 2-9-26 2-8-24 2-8-23 2-7-22 2-7-21 2-7-19 2
pregnanetriol 4245-14-39 7-22-60 7-22-60 7-22-60 7-22-60 7-22-60 7-22-60 7-22-60 7
pregnenetriol 4244-15-58 7-28-109 10-40-156 
12-45-
173 
10-40-
153 9-34-132 8-30-115 6-23-89 5
pregnanetriolone 4241-4-12 1-4-12 1-3-11 1-3-11 1-3-10 1-3-10 1-3-9 1-3-9 1
5α-DH-progesterone 3614-23-118 5-31-159 6-39-195 7-44-220 7-45-228 7-43-216 6-39-196 5-33-165 4142
3α5α-TH-progesterone 3610-1-4 1-2-5 1-2-5 1-2-6 1-2-6 1-2-7 1-2-7 1-2-7 1
3β5α-TH-progesterone 3621-3-10 1-4-11 1-4-11 1-4-11 1-3-10 1-3-9 1-2-7 0-2-5 0
3α5β-TH-progesterone 3610-1-5 0-1-4 0-1-4 0-1-3 0-1-3 0-1-3 0-1-3 0-1-2 0
3β5β-TH-progesterone 3620-3-12 0-4-16 0-5-20 1-6-25 1-7-28 1-8-30 1-8-30 1-8-30 1
20α-DH-progesterone 3609-127-514 4-60-243 2-31-126 1-18-71 1-11-44 1-7-29 0-5-22 0-4-15 0
17α-OH-20α-DH-
progesterone 3621-9-52 1-9-52 1-9-52 1-9-52 1-9-52 1-9-52 1-9-52 1-9-52 1
20aDH3α5aTHprogesterone 3622-13-42 2-10-35 1-9-29 1-7-25 1-6-21 1-5-19 1-5-16 1-4-13 1
20aDH3β5αTHprogesterone 3611-4-28 1-4-25 1-3-22 1-3-19 0-3-17 0-2-16 0-2-14 0-2-12 0
20α-DH-3α5β-TH-
progesterone 4221-9-39 1-7-28 1-5-23 1-5-20 1-5-20 1-5-20 1-5-20 1-5-20 1
20α-DH-3β5β-TH-
progesterone 3621-7-89 2-9-110 2-9-115 1-8-103 1-7-87 1-6-74 1-5-63 1-4-49 1
20β-DH-progesterone 3629-92-389 6-64-272 4-46-193 3-33-140 2-25-104 2-19-78 1-14-60 1-9-38 1
dehydroepiandrosterone 4242-9-38 2-7-32 2-6-27 2-5-23 1-5-20 1-4-18 1-4-16 1-3-13 1
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16α-OH-
dehydroepiandrosterone 424
136-
1088-
8720 
123-985-
7898 
94-757-
6070 
62-494-
3959 
38-301-
2414 
24-189-
1515 
15-122-
979 7-56-446 
4
228
androstenediol 4248-29-131 7-25-110 6-21-94 5-18-80 4-15-69 4-13-60 3-12-52 3-9-41 2
testosterone 4241-7-60 1-5-48 1-4-39 1-3-32 0-3-27 0-2-23 0-2-19 0-2-15 0
androsterone 4244-10-27 5-14-38 6-15-40 5-13-36 4-12-32 4-11-29 4-10-27 3-8-23 3
5-androstenetriol 424
395-
1656-
6005 
385-
1612-
5846 
329-
1376-
4990 
246-
1030-
3735 
165-689-
2499 
110-462-
1676 
76-317-
1148 
38-159-
575 
21
314
11β-OH-androsterone 4242-6-18 4-9-28 5-12-40 7-17-54 9-21-67 10-24-78 11-26-84 11-26-84 1184
etiocholanolone 4241-3-15 1-3-13 1-3-12 1-2-11 1-2-10 1-2-10 1-2-10 1-2-10 1
estradiol 4210-1-4 0-1-3 0-1-3 0-1-3 0-1-3 0-1-2 0-1-2 0-0-2 0
estriol 42423-120-510 7-35-149 4-19-80 2-12-49 1-7-31 1-5-20 1-3-14 0-2-7 0
11-dehydro-TH-
corticosterone 420
16-81-
1265 
19-98-
1531 
22-112-
1754 
24-121-
1901 
25-124-
1950 
24-121-
1894 
22-111-
1740 
17-85-
1338 
13
1056
TH-corticosterone 4248-26-71 8-25-68 8-24-65 7-23-63 7-22-60 7-22-58 7-21-57 6-20-54 6
allo-TH-corticosterone 4235-28-109 2-9-35 2-10-39 3-14-53 3-18-69 4-23-90 5-30-115 8-46-178 12257
TH-aldosterone 4235-22-89 5-22-89 5-22-89 5-22-89 5-22-89 5-22-89 5-22-89 5-22-89 5
TH-11-deoxycortisol 4246-20-51 4-13-33 3-11-27 3-10-26 3-10-26 3-10-26 3-10-26 3-10-26 3
cortisol 42420-53-127 
18-46-
110 15-40-96 14-35-84 12-31-75 11-28-67 10-25-61 8-21-51 7
6β-OH-cortisol 4210-3-27 0-1-14 0-1-15 0-2-17 0-2-19 0-2-22 0-2-24 0-3-29 1
20α-DH-cortisol 4210-1-6 0-1-6 0-1-6 0-1-6 0-1-6 0-1-7 0-1-7 0-1-9 0
TH-cortisol 4242-5-15 2-6-17 3-7-21 3-9-27 5-12-36 6-16-48 8-20-61 12-32-97 18143
α-cortol 42416-49-145 
23-74-
216 
27-85-
249 
25-79-
232 
23-72-
210 
21-66-
192 
19-60-
177 
17-52-
153 
15
137
β-cortol 4244-11-24 6-15-35 8-21-47 10-27-60 13-33-73 15-38-85 16-42-94 17-44-100 
17
100
11β-OH-etiocholanolone 4243-15-111 3-19-142 4-22-159 4-21-158 3-20-147 3-19-137 3-17-129 3-16-114 2103
cortisone 42424-83-194 
24-84-
197 
23-82-
192 
22-77-
180 
20-69-
162 
17-61-
141 
15-53-
124 12-42-98 
10
80
20α-DH-cortisone 4246-22-65 6-24-69 6-24-71 6-24-69 6-22-64 5-20-58 4-17-50 3-13-37 3
20β-DH-cortisone 4244-13-32 6-17-43 7-20-52 7-22-55 7-21-52 6-18-46 6-16-41 5-14-34 4
TH-cortisone 424186-536-1328 
208-601-
1488 
226-652-
1616 
238-688-
1703 
244-703-
1741 
241-697-
1726 
232-670-
1659 
204-588-
1456 
181
522
1294
1β-OH-TH-cortisone 40549-152-412 
42-130-
352 
36-112-
305 
32-98-
266 
28-86-
235 
25-77-
210 
23-70-
190 
19-59-
161 
17
142
6α-OH-TH-cortisone 405
942-
2679-
6011 
987-
2805-
6294 
984-
2798-
6279 
936-
2660-
5968 
847-
2408-
5405 
731-
2078-
4662 
618-
1758-
3945 
456-
1295-
2906 
349
991
2224
α-cortolone 42414-36-89 34-89-221 
46-120-
299 
46-120-
299 
46-120-
299 
46-120-
299 
46-120-
299 
46-120-
299 
46
299
β-cortolone 42471-200-449 
113-316-
709 
150-420-
942 
167-470-
1053 
157-442-
991 
136-383-
859 
119-335-
750 
93-261-
586 
75
472
1β-OH-β-cortolone 405106-413-1405 
69-268-
911 
46-179-
609 
32-124-
421 
23-88-
301 
17-65-
222 
13-50-
169 8-32-108 6
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6α-OH-β-cortolone 405
417-
1089-
3139 
340-888-
2560 
273-712-
2052 
215-561-
1617 
166-434-
1252 
127-331-
953 
96-252-
725 
59-153-
442 
38
289
11-keto-etiocholanolone 4248-43-193 8-40-179 7-37-167 7-35-156 6-33-147 6-31-138 6-29-130 5-26-118 5107
Table 4. Fifteen urinary steroid metabolites at 13 time-points in the first year of life 
display sex specificity. Age and sex dependency of each log-transformed steroid has been 
estimated the described statistical models. Data are presented as 10th-50th-90th percentiles 
and expressed in the unit μg / mmol creatinine. The association with age effect is indicated. N 
represents the sample number per analyte, included in the statistical model. m: male, f: 
female 
    Week 1 Week 3 Week 5 Week 7 Week 9 Week 11 Week 13 Week 17
Metabolite sexN 10
th-50th-
90th 
10th-50th-
90th 
10th-50th-
90th 
10th-50th-
90th 
10th-50th-
90th 
10th-50th-
90th 
10th-50th-
90th 
10th-50
90th 
progesterone m 1663-290-1865 
2-198-
1274 1-139-896 1-101-649 1-75-484 1-58-372 1-46-294 0-31-
f 1961-119-768 1-82-525 1-57-369 0-42-267 0-31-199 0-24-153 0-19-121 0-13-
11α-OH-
progesterone 
m 1662-139-648 2-122-566 2-107-499 1-95-443 1-85-397 1-77-359 1-70-328 1-60-
f 1961-63-291 1-55-254 1-48-224 1-43-199 1-38-178 1-35-161 1-32-147 0-27-
11β-OH-
progesterone 
m 1651-11-124 1-11-124 1-11-124 1-11-124 1-11-124 1-11-124 1-11-124 1-11-
f 1950-5-57 0-5-57 0-5-57 0-5-57 0-5-57 0-5-57 0-5-57 0-5-57
11-keto-
progesterone 
m 1661-59-4062 1-47-3234 1-38-2606 0-31-2125 0-25-1754 0-21-1465 0-18-1239 0-13-
f 1962-113-7801 1-90-6211 1-72-5005 1-59-4081 1-49-3369 1-41-2814 1-34-2379 0-26-
5β-DH-
progesterone 
m 1662-21-169 2-16-129 1-12-101 1-10-80 1-8-65 1-7-53 1-6-45 1-4-34
f 1961-10-79 1-7-61 1-6-47 1-5-37 0-4-30 0-3-25 0-3-21 0-2-16
6α-OH-3α5β-
TH-
progesterone 
m 16640-162-718 28-114-504 20-82-363 15-61-270 12-46-206 9-37-162 7-30-131 5-21-
f 19672-292-1294 
51-205-
908 37-148-655 27-110-486 21-84-371 16-66-292 13-53-236 9-38-
20α-DH-5α-
DH-
progesterone 
m 16681-25650-136837 
44-13883-
74063 
25-7818-
41707 
15-4580-
24435 
9-2792-
14894 
6-1771-
9445 
4-1168-
6232 
2-573
3055 
f 19626-8189-43682 
14-4432-
23644 
8-2496-
13314 
5-1462-
7801 3-891-4755 
2-565-
3015 
1-373-
1990 1-183
5α-DH-
testosterone 
m 1963-27-185 4-33-226 5-38-258 5-40-274 5-40-272 4-37-251 4-32-219 3-25-
f 2282-15-101 2-18-124 2-21-141 3-22-150 3-22-148 2-20-137 2-18-120 2-13-
androstanediol m 1952-44-452 2-44-452 2-44-452 2-44-452 2-44-452 2-44-452 2-44-452 2-44-f 2281-20-210 1-20-210 1-20-210 1-20-210 1-20-210 1-20-210 1-20-210 1-20-
Deoxy-
corticosterone 
m 1663-38-216 1-20-113 1-13-77 1-12-67 1-12-67 1-12-67 1-12-67 1-12-
f 1961-15-88 1-8-46 0-6-31 0-5-28 0-5-28 0-5-28 0-5-28 0-5-28
11-deoxy-TH-
corticosterone 
m 1952-25-626 2-21-514 2-17-427 1-14-359 1-12-305 1-11-263 1-9-229 1-7-180
f 2281-9-233 1-8-191 1-6-159 1-5-133 0-5-113 0-4-98 0-3-85 0-3-67
18-OH-11-
DH-TH-
corticosterone 
m 1960-5-147 0-5-147 0-5-147 0-5-147 0-5-147 0-5-147 0-5-147 0-5-147
f 2280-2-74 0-2-74 0-2-74 0-2-74 0-2-74 0-2-74 0-2-74 0-2-74
18-OH-
cortisol 
m 1930-1-568 0-1-568 0-1-568 0-1-568 0-1-568 0-1-568 0-1-568 0-1-568
f 2260-1-296 0-1-296 0-1-296 0-1-296 0-1-296 0-1-296 0-1-296 0-1-296
allo-TH-
cortisol 
m 1961-5-14 3-10-31 6-21-63 12-39-120 20-70-211 33-114-346 
51-173-
526 
93-318
966 
f 2281-3-8 2-6-17 3-11-35 6-22-66 11-39-117 19-63-192 28-96-291 52-176
Page 22 of 24 
    Week 1 Week 3 Week 5 Week 7 Week 9 Week 11 Week 13 Week 17
534 
6α-OH-α-
cortolone 
m 1782832-7636-18456 
3365-
9073-
21927 
3740-
10085-
24373 
3890-
10488-
25347 
3784-
10204-
24662 
3445-
9289-
22449 
3044-
8208-
19836 
2428-
6546-
15819
f 2271914-5162-12475 
2274-
6132-
14821 
2528-6816-
16474 
2629-7089-
17132 
2558-6897-
16669 
2328-
6278-
15174 
2057-
5548-
13408 
1641-
4424-
10693
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